Cargando…

Tumor infiltrating lymphocytes (TILs) are a prognosis biomarker in Colombian patients with triple negative breast cancer

Triple negative breast cancer (TNBC) is highly immunogenic and high levels of tumor infiltrating lymphocytes (TILs) have been associated with a better prognosis and higher probability to achieve pathological complete response. Here, we explore the potential role of stromal TILs level and composition...

Descripción completa

Detalles Bibliográficos
Autores principales: Huertas-Caro, Carlos A., Ramírez, Mayra A., Rey-Vargas, Laura, Bejarano-Rivera, Lina María, Ballen, Diego Felipe, Nuñez, Marcela, Mejía, Juan Carlos, Sua-Villegas, Luz Fernanda, Cock-Rada, Alicia, Zabaleta, Jovanny, Fejerman, Laura, Sanabria-Salas, María Carolina, Serrano-Gomez, Silvia J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10694133/
https://www.ncbi.nlm.nih.gov/pubmed/38044375
http://dx.doi.org/10.1038/s41598-023-48300-4
_version_ 1785153306124877824
author Huertas-Caro, Carlos A.
Ramírez, Mayra A.
Rey-Vargas, Laura
Bejarano-Rivera, Lina María
Ballen, Diego Felipe
Nuñez, Marcela
Mejía, Juan Carlos
Sua-Villegas, Luz Fernanda
Cock-Rada, Alicia
Zabaleta, Jovanny
Fejerman, Laura
Sanabria-Salas, María Carolina
Serrano-Gomez, Silvia J.
author_facet Huertas-Caro, Carlos A.
Ramírez, Mayra A.
Rey-Vargas, Laura
Bejarano-Rivera, Lina María
Ballen, Diego Felipe
Nuñez, Marcela
Mejía, Juan Carlos
Sua-Villegas, Luz Fernanda
Cock-Rada, Alicia
Zabaleta, Jovanny
Fejerman, Laura
Sanabria-Salas, María Carolina
Serrano-Gomez, Silvia J.
author_sort Huertas-Caro, Carlos A.
collection PubMed
description Triple negative breast cancer (TNBC) is highly immunogenic and high levels of tumor infiltrating lymphocytes (TILs) have been associated with a better prognosis and higher probability to achieve pathological complete response. Here, we explore the potential role of stromal TILs level and composition as a prognostic and predictive biomarker in TNBC. 195 Tumor biospecimens from patients diagnosed with TNBC were included. Stromal TILs (sTILs), positive CD4/CD8 cells were evaluated. Differences in clinic-pathological characteristics according to immune infiltration were assessed. The predictive and prognostic value of immune infiltration was analyzed by multivariate models. Higher immune infiltration was observed in patients with favorable clinical–pathological features. Survival analysis showed that longer overall survival times were observed in patients with a higher infiltration of sTILs (p = 0.00043), CD4 + (p = 0.0074) and CD8 + (p = 0.008). In the multivariate analysis, low levels of sTILs were found to be associated with a higher mortality hazard (HR: 1.59, 95% CI 1.01–2.48). CD4 and CD8 immune infiltration were associated with higher odds for pathological complete response (OR: 1.20, 95% CI 1.00–1.46, OR: 1.28, 1.02–1.65, respectively). Our results suggest that immune infiltration could be used as a prognostic marker for overall survival in TNBC patients.
format Online
Article
Text
id pubmed-10694133
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-106941332023-12-05 Tumor infiltrating lymphocytes (TILs) are a prognosis biomarker in Colombian patients with triple negative breast cancer Huertas-Caro, Carlos A. Ramírez, Mayra A. Rey-Vargas, Laura Bejarano-Rivera, Lina María Ballen, Diego Felipe Nuñez, Marcela Mejía, Juan Carlos Sua-Villegas, Luz Fernanda Cock-Rada, Alicia Zabaleta, Jovanny Fejerman, Laura Sanabria-Salas, María Carolina Serrano-Gomez, Silvia J. Sci Rep Article Triple negative breast cancer (TNBC) is highly immunogenic and high levels of tumor infiltrating lymphocytes (TILs) have been associated with a better prognosis and higher probability to achieve pathological complete response. Here, we explore the potential role of stromal TILs level and composition as a prognostic and predictive biomarker in TNBC. 195 Tumor biospecimens from patients diagnosed with TNBC were included. Stromal TILs (sTILs), positive CD4/CD8 cells were evaluated. Differences in clinic-pathological characteristics according to immune infiltration were assessed. The predictive and prognostic value of immune infiltration was analyzed by multivariate models. Higher immune infiltration was observed in patients with favorable clinical–pathological features. Survival analysis showed that longer overall survival times were observed in patients with a higher infiltration of sTILs (p = 0.00043), CD4 + (p = 0.0074) and CD8 + (p = 0.008). In the multivariate analysis, low levels of sTILs were found to be associated with a higher mortality hazard (HR: 1.59, 95% CI 1.01–2.48). CD4 and CD8 immune infiltration were associated with higher odds for pathological complete response (OR: 1.20, 95% CI 1.00–1.46, OR: 1.28, 1.02–1.65, respectively). Our results suggest that immune infiltration could be used as a prognostic marker for overall survival in TNBC patients. Nature Publishing Group UK 2023-12-03 /pmc/articles/PMC10694133/ /pubmed/38044375 http://dx.doi.org/10.1038/s41598-023-48300-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Huertas-Caro, Carlos A.
Ramírez, Mayra A.
Rey-Vargas, Laura
Bejarano-Rivera, Lina María
Ballen, Diego Felipe
Nuñez, Marcela
Mejía, Juan Carlos
Sua-Villegas, Luz Fernanda
Cock-Rada, Alicia
Zabaleta, Jovanny
Fejerman, Laura
Sanabria-Salas, María Carolina
Serrano-Gomez, Silvia J.
Tumor infiltrating lymphocytes (TILs) are a prognosis biomarker in Colombian patients with triple negative breast cancer
title Tumor infiltrating lymphocytes (TILs) are a prognosis biomarker in Colombian patients with triple negative breast cancer
title_full Tumor infiltrating lymphocytes (TILs) are a prognosis biomarker in Colombian patients with triple negative breast cancer
title_fullStr Tumor infiltrating lymphocytes (TILs) are a prognosis biomarker in Colombian patients with triple negative breast cancer
title_full_unstemmed Tumor infiltrating lymphocytes (TILs) are a prognosis biomarker in Colombian patients with triple negative breast cancer
title_short Tumor infiltrating lymphocytes (TILs) are a prognosis biomarker in Colombian patients with triple negative breast cancer
title_sort tumor infiltrating lymphocytes (tils) are a prognosis biomarker in colombian patients with triple negative breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10694133/
https://www.ncbi.nlm.nih.gov/pubmed/38044375
http://dx.doi.org/10.1038/s41598-023-48300-4
work_keys_str_mv AT huertascarocarlosa tumorinfiltratinglymphocytestilsareaprognosisbiomarkerincolombianpatientswithtriplenegativebreastcancer
AT ramirezmayraa tumorinfiltratinglymphocytestilsareaprognosisbiomarkerincolombianpatientswithtriplenegativebreastcancer
AT reyvargaslaura tumorinfiltratinglymphocytestilsareaprognosisbiomarkerincolombianpatientswithtriplenegativebreastcancer
AT bejaranoriveralinamaria tumorinfiltratinglymphocytestilsareaprognosisbiomarkerincolombianpatientswithtriplenegativebreastcancer
AT ballendiegofelipe tumorinfiltratinglymphocytestilsareaprognosisbiomarkerincolombianpatientswithtriplenegativebreastcancer
AT nunezmarcela tumorinfiltratinglymphocytestilsareaprognosisbiomarkerincolombianpatientswithtriplenegativebreastcancer
AT mejiajuancarlos tumorinfiltratinglymphocytestilsareaprognosisbiomarkerincolombianpatientswithtriplenegativebreastcancer
AT suavillegasluzfernanda tumorinfiltratinglymphocytestilsareaprognosisbiomarkerincolombianpatientswithtriplenegativebreastcancer
AT cockradaalicia tumorinfiltratinglymphocytestilsareaprognosisbiomarkerincolombianpatientswithtriplenegativebreastcancer
AT zabaletajovanny tumorinfiltratinglymphocytestilsareaprognosisbiomarkerincolombianpatientswithtriplenegativebreastcancer
AT fejermanlaura tumorinfiltratinglymphocytestilsareaprognosisbiomarkerincolombianpatientswithtriplenegativebreastcancer
AT sanabriasalasmariacarolina tumorinfiltratinglymphocytestilsareaprognosisbiomarkerincolombianpatientswithtriplenegativebreastcancer
AT serranogomezsilviaj tumorinfiltratinglymphocytestilsareaprognosisbiomarkerincolombianpatientswithtriplenegativebreastcancer